Article Text

Download PDFPDF
CASE REPORT
Metformin-associated lactic acidosis treated with continuous renal replacement therapy
  1. Akihide Nakamura1,2,
  2. Kei Suzuki1,2,
  3. Hiroshi Imai2,
  4. Naoyuki Katayama1
  1. 1Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan
  2. 2Mie University Hospital, The Emergency and Critical Care Center, Tsu, Japan
  1. Correspondence to Dr Kei Suzuki, keis{at}clin.medic.mie-u.ac.jp

Summary

Metformin-associated lactic acidosis (MALA) is a rare but life-threatening complication. We report a case of MALA in a man aged 71 years who was treated with continuous renal replacement therapy (CRRT). The patient was brought to the hospital for prolonged and gradual worsening gastrointestinal symptoms. Although he received intravenous treatment, he developed catecholamine-resistant shock, and blood gas analysis revealed lactic acidosis. Bicarbonate and antibiotics for possible sepsis were initiated, but with no clear benefit. Owing to haemodynamic instability with metabolic acidosis, urgent CRRT was given: it was immediately effective in reducing lactate levels; pH values completely normalised within 18 hours, and he was stabilised. MALA sometimes presents with non-specific symptoms, and is important to consider when treating unexplainable metabolic acidosis. In severe cases, CRRT has potential merit, particularly in haemodynamically unstable patients. It is important to be familiar with MALA as a medical emergency, even for emergency physicians.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors KS and AN collected the data and drafted the manuscript. KS, AN and HI were involved in the treatment of the patient. NK revised and edited the manuscript. All authors have read and approved the final version of the manuscript.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.